Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome

This study has been completed.

First Received: October 18, 1999 Last Updated: June 23, 2005 History of Changes

Sponsors and Collaborators:	National Center for Research Resources (NCRR) University of Michigan
Information provided by:	National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:	NCT00004326

Purpose

OBJECTIVES: I. Evaluate whether chronic hypercortisolemia is specifically toxic to hippocampal cells and causes structural reduction of hippocampal volume in patients with Cushing's syndrome. II. Determine whether reduced hippocampal volume is associated with specific memory dysfunction.

III. Examine the relationships of adrenal androgen to hippocampal volume and memory dysfunction.

IV. Examine the reversibility of hippocampal structural changes and cognitive dysfunction after cortisol levels are normalized.

Condition
Cushing's Syndrome

MedlinePlus related topics: Cushing's Syndrome Memory

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening

Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment:	12
Study Start Date:	August 1994

Detailed Description:

PROTOCOL OUTLINE: Patients undergo a psychiatric evaluation for mood and cognition during confirmation of diagnosis. Neuropsychologic exams include pencil and paper test and a cognitive assessment. Endocrine studies include dexamethasone and corticotropin-releasing hormone stimulation tests. The hippocampal complex volume is assessed with coronal magnetic resonance imaging. There is a follow-up 1 year after the initiation of treatment.

Eligibility

Ages Eligible for Study:	15 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

Adults and teenagers with untreated, spontaneous active Cushing's syndrome
Diagnosis verified at the University of Michigan Medical Center, including the following: Excessive cortisol secretion measured by urinary-free cortisol, cortisol secretion rate, and plasma cortisol level
Lack of normal circadian cortisol secretion and failure to suppress following 2 mg of dexamethasone

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004326

Locations

United States, Michigan
University of Michigan Health Systems
Ann Arbor, Michigan, United States, 48109

Sponsors and Collaborators

National Center for Research Resources (NCRR)

University of Michigan

Investigators

Study Chair:

Monica N. Starkman

University of Michigan

More Information

No publications provided

Study ID Numbers:	199/11872, UMMC-1043
Study First Received:	October 18, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00004326 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):

Cushing's syndrome
endocrine disorders
rare disease

Study placed in the following topic categories:

Rare Diseases
Cushing Syndrome
Adrenal Gland Diseases

Endocrine System Diseases
Endocrinopathy
Adrenocortical Hyperfunction

Additional relevant MeSH terms:

Pathologic Processes
Disease
Syndrome
Cushing Syndrome

Endocrine System Diseases
Adrenal Gland Diseases
Adrenocortical Hyperfunction

ClinicalTrials.gov processed this record on May 07, 2009